Immunization with a Replication-defective Herpes Simplex Virus 2 Mutant Reduces Herpes Simplex Virus 1 Infection and Prevents Ocular Disease

Overview

Journal Virology

Specialty Microbiology

Date 2007 Oct 5

PMID 17915278

Citations 16

Authors

Allison L van Lint

Ernesto Torres-Lopez

David M Knipe

Affiliations

Soon will be listed here.

Abstract

Ocular infections with herpes simplex virus 1 can lead to corneal scarring and blindness, with herpes keratitis being the major infectious cause of blindness. There is currently no clinically approved vaccine and nearly all developmental vaccines are targeted against HSV-2 and genital herpes. We tested the ability of an HSV-2 replication-defective virus, a genital herpes vaccine candidate, to protect against HSV-1 corneal infection. Immunization with HSV-2 dl5-29 reduced viral replication in the cornea, prevented ocular disease and reduced latent infection by the HSV-1 strain. Therefore, this HSV-2 replication-defective mutant strain may have applications for prevention of herpes keratitis and genital herpes due to HSV-1 infection.

Citing Articles

A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

Ramsey N, Visciano M, Hunte R, Loh L, Aschner C, Jacobs Jr W J Virol. 2020; 94(13).

PMID: 32295919 PMC: 7307146. DOI: 10.1128/JVI.00335-20.

Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.

Patel C, Backes I, Taylor S, Jiang Y, Marchant A, Pesola J Sci Transl Med. 2019; 11(487).

PMID: 30971454 PMC: 6681804. DOI: 10.1126/scitranslmed.aau6039.

Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.

Rao P, Wen X, Lo J, Kim S, Li X, Chen S J Virol. 2018; 92(22).

PMID: 30185591 PMC: 6206489. DOI: 10.1128/JVI.01490-18.

Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.

Davido D, Tu E, Wang H, Korom M, Gazquez Casals A, Reddy P J Virol. 2018; 92(17).

PMID: 29950407 PMC: 6096795. DOI: 10.1128/JVI.01036-18.

Analysis of Herpes Simplex Virus Reactivation in Explant Reveals a Method-Dependent Difference in Measured Timing of Reactivation.

Doll J, Sawtell N J Virol. 2017; 91(16).

PMID: 28637763 PMC: 5533896. DOI: 10.1128/JVI.00848-17.

References

Nesburn A, Slanina S, Burke R, Ghiasi H, Bahri S, Wechsler S . Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol. 1998; 72(10):7715-21. PMC: 110076. DOI: 10.1128/JVI.72.10.7715-7721.1998. View

Bourne N, Bravo F, Francotte M, Bernstein D, Myers M, Slaoui M . Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis. 2003; 187(4):542-9. DOI: 10.1086/374002. View

Malkin J . Epidemiology of genital herpes simplex virus infection in developed countries. Herpes. 2004; 11 Suppl 1:2A-23A. View

Katz J, Bodin E, Coen D . Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J Virol. 1990; 64(9):4288-95. PMC: 247895. DOI: 10.1128/JVI.64.9.4288-4295.1990. View

Corey L, Wald A, Celum C, Quinn T . The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004; 35(5):435-45. DOI: 10.1097/00126334-200404150-00001. View

Morrison L, Knipe D . Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol. 1994; 68(2):689-96. PMC: 236504. DOI: 10.1128/JVI.68.2.689-696.1994. View

Da Costa X, Kramer M, Zhu J, Brockman M, Knipe D . Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol. 2000; 74(17):7963-71. PMC: 112327. DOI: 10.1128/jvi.74.17.7963-7971.2000. View

Xu F, Sternberg M, Kottiri B, McQuillan G, Lee F, Nahmias A . Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006; 296(8):964-73. DOI: 10.1001/jama.296.8.964. View

Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss H, Vergne L . Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007; 356(8):790-9. DOI: 10.1056/NEJMoa062607. View

10.

Freeman E, Weiss H, Glynn J, Cross P, Whitworth J, Hayes R . Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2005; 20(1):73-83. DOI: 10.1097/01.aids.0000198081.09337.a7. View

11.

Koelle D, Corey L . Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003; 16(1):96-113. PMC: 145296. DOI: 10.1128/CMR.16.1.96-113.2003. View

12.

Da Costa X, Jones C, Knipe D . Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A. 1999; 96(12):6994-8. PMC: 22033. DOI: 10.1073/pnas.96.12.6994. View

13.

Sawtell N, Thompson R, Stanberry L, Bernstein D . Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis. 2001; 184(8):964-71. DOI: 10.1086/323551. View

14.

Verjans G, Remeijer L, van Binnendijk R, Cornelissen J, Volker-Dieben H, Baarsma S . Identification and characterization of herpes simplex virus-specific CD4+ T cells in corneas of herpetic stromal keratitis patients. J Infect Dis. 1998; 177(2):484-8. DOI: 10.1086/517382. View

15.

Sawtell N . The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol. 1998; 72(8):6888-92. PMC: 109900. DOI: 10.1128/JVI.72.8.6888-6892.1998. View

16.

Hoshino Y, Dalai S, Wang K, Pesnicak L, Lau T, Knipe D . Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol. 2004; 79(1):410-8. PMC: 538700. DOI: 10.1128/JVI.79.1.410-418.2005. View

17.

Liesegang T . Herpes simplex virus epidemiology and ocular importance. Cornea. 2001; 20(1):1-13. DOI: 10.1097/00003226-200101000-00001. View

18.

DAWSON C, Togni B . Herpes simplex eye infections: clinical manifestations, pathogenesis and management. Surv Ophthalmol. 1976; 21(2):121-35. DOI: 10.1016/0039-6257(76)90090-4. View

19.

Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L . Genital shedding of herpes simplex virus among men. J Infect Dis. 2002; 186 Suppl 1:S34-9. DOI: 10.1086/342969. View

20.

McKnight S . The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acids Res. 1980; 8(24):5949-64. PMC: 328064. DOI: 10.1093/nar/8.24.5949. View